1. Repositório Institucional da UFMG
2. Publicações Científicas e Culturais
3. Artigo de Periódico

Type:	Artigo de Periódico
Title:	Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy
Authors:	Fillipe Luiz Rosado Carmo Houem Rabah Barbara Fernandes Cordeiro Sara Heloisa da Silva Rafaela Miranda Pessoa Simone Odília Antunes Fernandes Valbert Nascimento Cardoso Valérie Gagnaire Martine Deplanche Bruna Savassi Alessandra Figueiroa Emiliano Rosa Oliveira Caio César Fonseca Maria Izabel Alves Queiroz Núbia Moraes Rodrigues Sávio Henrique de Cicco Sandes Álvaro Cantini Nunes Luisa Lemos Juliana de Lima Alves Ana Maria Caetano Faria Ênio Ferreira Yves Le Loir Gwénaël Jan Vasco Azevedo
Abstract:	Propionibacterium freudenreichii CIRM-BIA 129 (P. freudenreichii wild type, WT) is a probiotic bacterium, which exerts immunomodulatory effects. This strain possesses extractable surface proteins, including SlpB, which are involved in anti-inflammatory effect and in adhesion to epithelial cells. We decided to investigate the impact of slpB gene mutation on immunomodulation in vitro and in vivo. In an in vitro assay, P. freudenreichii WT reduced expression of IL-8 (p<0.0001) and TNF-α (p<0.0001) cytokines in LPS-stimulated HT-29 cells. P. freudenreichii ΔslpB, lacking the SlpB protein, failed to do so. Subsequently, both strains were investigated in vivo in a 5-FU-induced mucositis mice model. Mucositis is a common side effect of cytotoxic chemotherapy with 5-FU, characterized by mucosal injury, inflammation, diarrhea, and weight loss. The WT strain prevented weight loss, reduced inflammation and consequently histopathological scores. Furthermore, it regulated key markers, including Claudin-1 (cld1, p<0.0005) and IL-17a (Il17a, p<0.0001) genes, as well as IL-12 (p<0.0001) and IL-1β (p<0.0429) cytokines levels. Mutant strain displayed opposite regulatory effect on cld1 expression and on IL-12 levels. This work emphasizes the importance of SlpB in P. freudenreichii ability to reduce mucositis inflammation. It opens perspectives for the development of probiotic products to decrease side effects of chemotherapy using GRAS bacteria with immunomodulatory surface protein properties.
Subject:	Probiótico Mucosite Quimioterapia
language:	eng
metadata.dc.publisher.country:	Brasil
Publisher:	Universidade Federal de Minas Gerais
Publisher Initials:	UFMG
metadata.dc.publisher.department:	FAR - DEPARTAMENTO DE ALIMENTOS FAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICAS ICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIA
Rights:	Acesso Aberto
metadata.dc.identifier.doi:	10.18632/oncotarget.27319
URI:	http://hdl.handle.net/1843/40862
Issue Date:	2020
metadata.dc.url.externa:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944450/
metadata.dc.relation.ispartof:	Oncotarget
Appears in Collections:	Artigo de Periódico

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.